Asset profile
Anti-CD33 CAR T-cells
Biologic (subtype unspecified)
Evidence outlook · results not reported
CART33 (NCT01864902) · Relapsed Adult Myeloid Leukemia, Chemotherapy Refractory Adult Myeloid Leukemia
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
CART33 (NCT01864902): This was a small, single-arm, open-label study with no comparator group, designed primarily to assess safety of this cell therapy in a heavily pretreated leukemia population. Results have not yet been posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 39 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Anti-CD33 CAR T-Cells: this drug | Phase 1/2 | Biologic (subtype unspecified) | CD33 | ||
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | ||
| Lintuzumab-Ac225 | Phase 3 | Radiopharmaceutical | CD33 | ||
| BL-M11D1 | Phase 2/3 | Antibody–drug conjugate | CD33 | ||
| PRGN-3006 T Cells | Phase 1 | Cell therapy | CD33 | ||
| ASTX727 | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | ||
| Enasidenib | Approved | Small molecule | IDH2 | ||
| Gilteritinib | Approved | Small molecule | FLT3 | ||
| Midostaurin | Approved | Small molecule | FLT3;KIT;PKC;PDGFR | ||
| Olutasidenib | Approved | Small molecule | Mutant IDH1 | ||
| Quizartinib | Approved | Small molecule | FLT3 | ||
| Revumenib | Approved | Small molecule | Menin | ||
| Tretinoin (Vesanoid) | Approved | Small molecule | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL | ||
| Venetoclax | Approved | Small molecule | BCL-2 | ||
| Vyxeos | Approved | Small molecule | DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II | ||
| 131I-Apamistamab | Phase 3 | Monoclonal antibody | CD45 |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
September 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.